eurofins discoverx

Eurofins DiscoverX, the products company of Eurofins Discovery, is committed to enabling and accelerating multi-modality drug discovery and development from discovery to QC lot release. For drug discovery and development scientists, Eurofins DiscoverX is the trusted product solutions provider that accelerates research and drug discovery programs with confidence for cytokine receptors, checkpoint receptors, GPCRs, kinases, ion channels, epigenetics, nuclear receptors, and other target families. Eurofins DiscoverX develops and manufactures cutting edge assays, stable cell lines, ready-to-use kits (including bioassays), membrane preps, enzymes, and reagents for small molecule and biologic immuno-oncology, cytotoxicity, compound-target engagement, potency and QC lot release, pharmacotrafficking, and many other applications. These products are developed from 3 R&D and manufacturing centers of excellence – San Francisco Bay Area California (Fremont); St. Louis area, Missouri (St. Charles); and Poitiers, France.

AnaptysBio

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

Plasmidsaurus

We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. Sequence Everything!

biomakers

BIOMAKERS es Centro de Medicina Genómica de Precisión y Biotecnología especializado en Análisis genómicos, Big Data y desarrollo de Tecnología para Oncología y otras áreas terapéuticas complejas en Latinoamérica y USA . Cuenta con Laboratorios Moleculares propios integrados en Argentina, Mexico y Brasil, en donde se llevan a cabo estudios de biomarcadores asociados al diagnóstico genómico-molecular y una Oficina de Big Data & Technology en San Francisco, USA. BIOMAKERS prioriza la innovación a partir de la incorporación de nuevas tecnologías a través de su departamento de I+D, y el desarrollo de Plataformas Tecnológicas con Inteligencia Artificial, junto con el desarrollo e implementación de nuevos estudios genéticos para 17 países de Latinoamérica, habiendo construido el BIOBANCO de tumores avanzados y el Dataset para cáncer más importante y grande de Latino América. BIOMAKERS está conformada por profesionales con amplia trayectoria en el ámbito científico, médico, de investigación clínica, y de desarrollo de tecnología quienes cuentan con lun expertise único en la región y conforman el grupo más experto de LATAM en Medicina de Precisión. BIOMAKERS se compromete con la comunidad, a través de políticas de responsabilidad social empresaria (RSE). Desde su fundación ha comenzado a trazar esta trayectoria, a través de campañas de difusión y capacitación de diversos entes sociales (proveedores, clientes, comunidad en general), así como también programas específicos de estudios genéticos en la población latinoamericana.

Connect Biopharma

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD. With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com